Test Price
2,800 AED✅ Home Collection Available
CD46 Gene (Atypical Hemolytic Uremic Syndrome Type 2) Susceptibility Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing (NGS) processing.
Premium Logistics: Temperature-controlled cold-chain home collection and VIP mobile phlebotomy available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic post-test counseling for result interpretation and complement inhibitor therapy eligibility assessment.
Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced next-generation sequencing (NGS) test analyzes the CD46 gene to identify pathogenic variants associated with susceptibility to atypical hemolytic uremic syndrome type 2 (aHUS type 2), a rare complement-mediated renal disorder characterized by thrombotic microangiopathy, hemolytic anemia, thrombocytopenia, and acute kidney injury. Detection of loss-of-function mutations in CD46 confirms hereditary predisposition and informs clinical management including complement inhibitor therapy and renal transplantation risk stratification.
| Feature | DNA Labs UAE NGS Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% analytical sensitivity for SNVs and small indels | Sanger sequencing (lower multiplexing, reduced sensitivity for mosaicism) |
| Methodology | NGS on Illumina platform, full CD46 gene coding regions and splice sites | Targeted mutation panel covering only common founder variants |
| Turnaround | 3–4 weeks | 4–6 weeks |
Physician Insight & Safety Protocols
“The CD46 gene plays a critical role in complement regulation. Pathogenic variants in CD46 account for a significant subset of atypical HUS cases and directly influence decisions regarding eculizumab therapy and renal allograft outcomes. This NGS-based test provides comprehensive coverage of the gene, but results must always be correlated with complement functional assays, family history, and clinical phenotype. I strongly recommend pre- and post-test genetic counseling for all patients pursuing this evaluation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory & Clinical Precautions
Medication Warning
Do not discontinue prescribed immunosuppressant, anticoagulant, or complement inhibitor therapy without consulting your treating physician. This genetic test is an elective diagnostic tool and does not replace urgent medical care during an acute hemolytic crisis.
Exclusion Criteria
- Patients unable to provide informed consent; minors require legal guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Active hemolytic crisis requiring emergency admission — this test is elective, not intended for acute triage.
- Specimen not collected and transported per validated cold-chain protocol — sample rejection will occur.
ER Red Flags
- Sudden drop in urine output, confusion, or seizures.
- Severe hypertension or signs of thrombotic microangiopathy (unexplained bruising, petechiae, schistocytes on smear).
- Immediate emergency medical attention required irrespective of genetic test status.
Patient FAQ & Clinical Guidance
1. Who should consider the CD46 gene susceptibility test for atypical HUS?
Individuals with a personal or family history of atypical hemolytic uremic syndrome, particularly those with early-onset renal failure, recurrent episodes, or a documented complement pathway abnormality, benefit most from this NGS-based test. It is also indicated for asymptomatic first-degree relatives of a proband with a confirmed CD46 pathogenic variant to establish genetic risk status prior to renal donation or prophylactic monitoring.
2. How does the CD46 NGS test guide treatment decisions?
A positive result identifying a pathogenic or likely pathogenic variant in CD46 confirms eligibility for complement inhibitor therapies such as eculizumab or ravulizumab under current UAE clinical guidelines. The test result also informs renal transplantation risk: patients with CD46 mutations have a lower risk of post-transplant recurrence compared to CFH or CFI variants, enabling more precise immunosuppression planning and donor selection.
3. What is the sample requirement and collection process?
We accept peripheral whole blood (3–5 mL in EDTA tube), extracted DNA (minimum 1 µg), or a single dried blood spot on an FTA card. A VIP mobile phlebotomist visits your home between 8 AM and 11 PM daily. The specimen is transported under strict temperature-controlled cold-chain conditions to our ISO-certified laboratory in Dubai Healthcare City. Results are typically available within 3–4 weeks of sample receipt.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with the UAE federal legislative framework governing genetic data, patient privacy, and clinical laboratory practice:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All genetic and clinical data are encrypted, access-controlled, and processed exclusively for diagnostic purposes with explicit patient consent.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Electronic health records and genomic data transmission adhere to mandated ICT security standards and interoperability protocols.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Patient consent, specimen handling, and result disclosure follow the statutory requirements for medical liability and professional accountability.
All testing is performed under the regulatory oversight of the Dubai Health Authority (DHA) and the UAE Ministry of Health and Prevention (MOHAP).
Clinical & Logistical Metadata
| Test Name | CD46 Gene (Atypical Hemolytic Uremic Syndrome Type 2) Susceptibility Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or dried blood spot (FTA card) — VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM–11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina platform, full CD46 gene coding regions and splice junctions |
| ICD-10-CM Code | D59.3 |
| LOINC Code | 81269-9 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians